Treatment of Human Melanoma with a Hapten‐Modified Autologous Vaccinea
- 1 August 1993
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 690 (1) , 147-152
- https://doi.org/10.1111/j.1749-6632.1993.tb44004.x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Prognostic Factors in Patients With Melanoma Metastatic to Axillary or Inguinal Lymph NodesAnnals of Surgery, 1991
- Drug-Induced Autoimmune and Hematologic DisordersImmunology and Allergy Clinics of North America, 1991
- Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.Journal of Clinical Oncology, 1990
- Constitutive expression of a phosphorylated activation antigen (Leu 23) by CD3bright human thymocytes.The Journal of Immunology, 1988
- The Induction of Hapten-Specific T Cell Tolerance by Using Hapten-Modified Lymphoid CellsThe Journal of Immunology, 1976
- Induction of immune responsiveness in a genetically low‐responsive tumor‐host combination by chemical modification of the immunogenEuropean Journal of Immunology, 1976
- Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activityNature, 1974
- Enhancement of Dinitrochlorobenzene (DNCB) Contact Sensitization by Cyclophosphamide in the Guinea PigJournal of Investigative Dermatology, 1967